Eddingpharm

Eddingpharm, established in 2001, is a prominent Chinese specialty pharmaceutical company operating within the Healthcare and Pharmaceuticals sectors. Headquartered in Kowloon, Hong Kong, the company focuses on the development, commercialization, and promotion of innovative therapeutic products. Its core product portfolio encompasses critical areas such as anti-infective drugs, treatments for respiratory system diseases, and advanced anti-cancer medications, underscoring its commitment to addressing significant health challenges.

With a workforce ranging from 500 - 1,000 employees, Eddingpharm maintains a significant operational footprint across its 3 locations. The company leverages its expertise in specialty pharmaceuticals to drive innovation and market penetration. For insights into the individuals driving its strategic initiatives and operational excellence, one can explore Meet Eddingpharm's team. This team structure supports its mission to deliver high-quality pharmaceutical solutions to patients and healthcare providers globally.

Financially, Eddingpharm has demonstrated substantial growth, reporting a revenue of $184.2M. The company has also secured significant investment through its funding rounds, including Series A in September 2009 and Series B in August 2010, attracting notable investors like Merrill Lynch, Domain Associates, OrbiMed, and Steamboat Ventures. These financial milestones highlight its robust market position and potential for future expansion. Further details on its financial performance and trajectory are available via Explore financial highlights.